Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

Table 1

HLA class I allele frequency.

HLA subtype	Alleles	ESRD		Control		OR	OR 95% CI	value
		n	%	n	%
HLA-A	A01	0	0	2	1.30	—	—	—
	A02	31	22.50	23	14.40	1.726	0.95–3.13	0.10
	A11	34	24.60	33	20.60	1.258	0.73–2.17	0.49
	A24	49	35.50	81	50.60	0.537	0.34–0.86	0.01
	A29	2	1.40	0	0	—	—	—
	A31	2	1.40	0	0	—	—	—
	A33	9	6.50	13	8.10	0.789	0.33–1.91	0.76
	A34	6	4.30	5	3.10	1.409	0.42–4.72	0.80
	A74	3	2.20	0	0	—	—	—
HLA-B	B07	4	2.90	4	2.50	1.164	0.29–4.74	1
	B08	2	1.40	0	0	—	—	—
	B13	7	5.10	3	1.90	2.796	0.71–11.03	0.23
	B15	52	37.70	62	38.80	0.956	0.60–1.53	0.94
	B18	15	10.90	16	10	1.098	0.52–2.31	0.95
	B27	8	5.80	8	5	1.169	0.43–3.20	0.96
	B35	5	3.60	17	10.60	0.316	0.11–0.88	0.02
	B38	8	5.80	11	6.90	0.834	0.33–2.14	0.89
	B39	4	2.90	2	1.30	2.358	0.43–13.08	0.55
	B40	8	5.80	8	5	1.169	0.43–3.20	0.96
	B44	4	2.90	12	7.50	0.368	0.12–1.17	0.13
	B51	7	5.10	11	6.90	0.724	0.27–1.92	0.69
	B52	1	0.70	2	1.30	0.577	0.05–6.43	1
	B56	3	2.20	2	1.30	1.756	0.29–10.66	0.86
	B58	3	2.20	1	0.60	3.533	0.36–34.36	0.52
HLA-C	C01	6	4.30	2	1.20	3.977	0.69–51.79	0.15
	C03	14	10.10	13	8.10	1.277	0.58–2.82	0.68
	C04	20	14.50	29	18.10	0.735	0.40–1.36	0.41
	C06	4	2.20	3	1.90	1.163	0.23–5.86	1
	C07	40	29.70	50	31.30	0.93	0.57–1.53	0.87
	C08	44	31.20	48	30	1.056	0.64–1.73	0.93
	C12	2	0.40	2	1.30	1.162	0.16–8.36	1
	C14	5	3.60	9	5.60	0.631	0.21–1.93	0.59
	C15	5	3.60	3	1.90	1.967	0.46–8.39	0.57

. HLA types with frequency >1% were performed in ESRD or control groups. HLA: human leukocyte antigen; ESRD: end-stage renal disease.